VESTED Quiz Game 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16.

Slides:



Advertisements
Similar presentations
HIV Counselling and Testing
Advertisements

Monica Gandhi MD, MPH Associate Professor and Women’s HIV Clinic provider, HIV/AIDS Division San Francisco General Hospital/ UCSF Safe Poz Love, U.S. Positive.
Switch to EVG/c/FTC/TDF  STRATEGY-PI Study  STRATEGY-NNRTI Study.
PROMISE Introduction to PROMISE Protocol May 6, 2009.
S AFETY OF I SONIAZID P REVENTIVE T HERAPY A MONG HIV- INFECTED P REGNANT W OMEN IN H IGH TB I NCIDENCE S ETTINGS : STUDY UPDATE OF IMPAACT P1078 (APPRISE)
MTN-028 Study Overview Phase 1 Pharmacokinetic Trial of Two Intravaginal Rings (IVRs) Containing Different Dose Strengths of Vicriviroc (MK-4176) and MK-2048.
A Collaborative Analysis of Data from Cohorts in Thailand, South Africa, Botswana, and the United Kingdom International Collaborative Study of Pediatric.
Presenter : Dr T. G. Nematadzira on behalf of The IMPAACT PROMISE 1077BF/1077FF Team Efficacy and Safety of Two Strategies to Prevent Perinatal HIV Transmission.
Pediatric ID Previous presentation by Susan Schuval, MD
Single-Dose Perinatal Nevirapine plus Standard Zidovudine to Prevent Mother to Child Transmission of HIV-1 in Thailand NEJM July 15, 2004 Lallemant et.
MTN-016 Training Protocol v2.0 MTN-016 EMBRACE: Evaluation of Maternal and Baby Outcomes Registry After Chemoprophylactic Exposure.
TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)
This presentation is intended for educational use only, and does not in any way constitute medical consultation or advice related to any specific patient.
Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.
1/11/01 Pediatric trials for ARV experienced children Coleen K. Cunningham Epidemiology of treatment experience in pediatrics How does the smaller number.
Looking Ahead to MTN-017 Ross D. Cranston MD, FRCP Microbicide Trials Network IRMA.
MATERNAL ANTIRETROVIRAL THERAPY AND INFANT OUTCOMES THROUGHOUT THE FIRST YEAR OF LIFE: results from the DREAM study in Dschang, Cameroon Taafo F, Doro.
HAART Initiation Within 2 Weeks of Seroconversion Associated With Virologic and Immunologic Benefits Slideset on: Hecht FM, Wang L, Collier A, et al. A.
Maternal clinical considerations
IMPAACT 2010 Eligibility Criteria
Maternal Toxicity Management
Rilpivirine-TDF-FTC versus Efavirenz-TDF-FTC STaR Trial
Maternal clinical considerations
IMPAACT 2010 Protocol Specifications for Recruitment, Screening, and Enrollment No updates.
Treatment-Naïve Adults
Clinical Case Scenarios
IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)
IMPAACT 2010 Screening Visits
RALTEGRAVIR vs LPV/R FOR LATE-PRESENTERS PREGNANT WOMEN.
STAND Trial NC-006 (M-Pa-Z) Dr Suzanne Staples Principal Investigator at THINK 26 Mar 2015.
IMPAACT 2010 Screening Visits
Dolutegravir plus Rilpivirine as Maintenance Dual Therapy SWORD-1 and SWORD- 2: Design
IMPAACT 2010 Eligibility Criteria
VESTED Quiz Game
Infant clinical considerations
A protocol in development IMPAACT Prevention Scientific Committee
2017 Key Considerations for adolescents and children & Key populations
On behalf of The MTN-020/ASPIRE Study Team
Etravirine in Treatment Experienced DUET-2 (TMC125-C216)
Clinical Case Scenarios
Delivery Visits: Key Concepts and Procedures
Maternal Toxicity Management
Expedited Adverse Event Reporting Requirements
Maternal Toxicity Management
Etravirine versus Protease Inhibitor in ARV-Experienced TMC 125-C227
Maternal clinical considerations
Switch RPV-TDF-FTC from NVP-Based Regimen NEAR-Rwanda Trial
Protocol References Section Title 6.2 Entry Visit 5.1
Clinical Case Scenarios
Dolutegravir versus Raltegravir in Treatment Experienced SAILING Study
Clinical Case Scenarios
Protocol References Section Title 6.2 Entry Visit 5.1
Delivery Visits: Key Concepts and Procedures
IMPAACT 2010 Eligibility Criteria
IMPAACT 2010 Eligibility Criteria
Phase 2 Treatment Naïve HIV Coinfection
IMPAACT 2010 Screening Visits
Expedited Adverse Event Reporting Requirements
What’s New in the Perinatal Guidelines
IMPAACT 2010 Pharmacy, Study Drug, and Concomitant Medication Considerations at Entry No updates.
Switch to DTG + 3TC ASPIRE Study.
Dorina Onoya1, Tembeka Sineke1, Alana Brennan1,2, Matt Fox1,2
Phase 3 Treatment Naïve HIV Coinfection
MTN-037 Protocol Overview
Adele Schwartz Benzaken
Switch to LPV/r monotherapy
Switch to LPV/r monotherapy
Switch to RAL-containing regimen
Facilitator: Pawin Puapornpong
Switch to LPV/r monotherapy
Presentation transcript:

VESTED Quiz Game 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

What are the primary objectives of VESTED?

Primary Objectives To determine: Whether treatment initiated during pregnancy with a DTG-containing regimen is superior to EFV/FTC/TDF with regard to virologic efficacy at delivery (HIV-1 RNA <200 copies/mL) Whether rates of the following safety outcomes differ for any pairwise regimen comparison Adverse pregnancy outcomes Maternal grade 3 or higher adverse events Infant grade 3 or higher adverse events

Describe the VESTED study design.

Study Design VESTED is a: Phase III Multi-site Three-arm Open-label study

How many secondary objectives are there? Four Seven Thirteen Too many to count I like this one!

Secondary Objectives

Describe the randomization in VESTED.

Briefly describe the VESTED study population.

Study Population VESTED will include: Approximately 549 HIV-1-infected pregnant women initiating antiretroviral therapy at 14-28 weeks gestation and their infants From sites in Botswana, Brazil, Haiti, India, Malawi, South Africa, Thailand, Uganda, the United States, Tanzania, and Zimbabwe

For how long will each maternal participant take part in the study? Added “maternal” to the question

Participant Follow-Up Each maternal participant will be followed for ~62-76 weeks ~12-26 weeks during pregnancy ~50 weeks after delivery Add “maternal” to the first part;

How many mother-infant pairs can be enrolled each month once the study opens to accrual?

will enroll the most mother-infant pairs Which site will enroll the most mother-infant pairs in VESTED?

List 3 of the VESTED inclusion criteria.

Inclusion Criteria See protocol Section 4.1

List 3 of the VESTED exclusion criteria.

Exclusion Criteria See protocol Section 4.2

What is the national animal of Botswana?

Mother infant pair! Ha – I love this!

study drugs that mothers in each VESTED arm will receive. Describe the study drugs that mothers in each VESTED arm will receive.

Arm 1: DTG+FTC/TAF Arm 2: DTG+FTC/TDF Arm 3: EFV/FTC/TDF

Name a procedure that is required at all scheduled maternal and infant study visits.

Procedures Required at All Scheduled Visits Medical history Physical examination

How is “ART naïve” defined in VESTED?

Definition of ART Naive Having not received prior antiretroviral therapy other than ARVs received during prior pregnancies or prior periods of breastfeeding (i.e., receipt of any single, dual, or triple ARV regimen during prior time-limited periods of pregnancy and breastfeeding is permitted). Receipt of up to 14 days of ARVs during the current pregnancy is permitted prior to study entry so that initiation of ARVs during the current pregnancy is not delayed during the study screening period

What maternal HIV-1 RNA assay must be used in VESTED?

Maternal HIV-1 RNA Assay Abbott RealTime Viral Load Assay

HIV nucleic acid test must be used in VESTED? What infant HIV nucleic acid test must be used in VESTED?

Infant HIV NAT Each site must use a test approved by the IMPAACT Laboratory Center for use at the site for diagnosis of infant HIV infection